<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-25 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-25</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-25</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-4da53b43c184eb9b9a3103a77957077abbc66474</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/4da53b43c184eb9b9a3103a77957077abbc66474" target="_blank">Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Thoracic Disease</p>
                <p><strong>Paper TL;DR:</strong> Current classification differentiates between preinvasive lesions (atypical adenomatous hyperplasia and in situ ADC), minimally invasive ADC (MIA) and invasive ADC, which allows more targeted treatments through two distinct strategies, genome-guided therapy and immunotherapy.</p>
                <p><strong>Cost:</strong> 0.023</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e25.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e25.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR L858R</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor L858R point mutation (exon 21)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A recurrent activating point mutation in EGFR (leucine->arginine at codon 858) that drives EGFR-dependent signaling in lung adenocarcinoma and predicts sensitivity to EGFR tyrosine kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR L858R</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK → RAS/RAF/MEK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>EGFR mutated in 10-16% overall; L858R accounts for ~45-50% of EGFR mutations (so ~4.5-8% overall)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; clinical response to targeted EGFR TKIs</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Described as an activating EGFR mutation that is oncogenic and confers sensitivity to EGFR tyrosine kinase inhibitors (clinical response evidence cited).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More frequent in non-smoking women and East Asian patients (in Asians EGFR mutation prevalence much higher).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Predicts sensitivity to EGFR TKIs (erlotinib, gefitinib, afatinib); osimertinib/other agents used for T790M resistance when present.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS/exon sequencing (TCGA), targeted PCR-based assays in clinical testing; also detectable by standard molecular diagnostics</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e25.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR exon19 del (E746_A750)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR exon 19 deletion (E746_A750del)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A recurrent in-frame deletion in exon 19 of EGFR that activates EGFR kinase and is a major sensitizing alteration to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR E746_A750 deletion (exon 19 deletion)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>small in-frame deletion (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK → RAS/RAF/MEK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>EGFR mutated in 10-16% overall; exon 19 deletions represent ~45% of EGFR mutations (so ~4.5-8% overall)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; clinical response to targeted EGFR TKIs</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Major sensitizing EGFR alteration demonstrating clinical responses to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Associated with better prognosis on EGFR-targeted therapy; more common in non-smokers and Asians.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Indicates first-line sensitivity to EGFR TKIs (erlotinib, gefitinib, afatinib).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS/exon sequencing (TCGA); PCR-based clinical assays</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e25.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR T790M</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR T790M resistance mutation (exon 20)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A secondary EGFR point mutation (threonine->methionine at codon 790) that commonly mediates acquired resistance to first- and second-generation EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR T790M</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (resistance)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK → RAS/RAF/MEK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>clinical resistance mechanism; genomic profiling of post-treatment tumors</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Confers resistance to early-generation EGFR TKIs; T790M-specific inhibitors (osimertinib and others) show activity.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Arises after TKI therapy as an acquired resistance mechanism.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable by third-generation EGFR inhibitors (osimertinib, olmutinib noted).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted mutation testing (PCR/NGS); clinical assays for resistance testing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e25.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Activating mutations in KRAS (most commonly codon 12) are the most frequent oncogenic drivers in lung adenocarcinoma and activate downstream MAPK signaling; historically difficult to target therapeutically.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS activating mutations (most commonly codon 12 substitutions such as G12C, G12V, G12D)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS / RAS → RAF → MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>~32% (TCGA 32.2%; cBioPortal ~33%)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; clinicopathologic correlation; prognostic studies</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Codon 12 mutations are activating RAS alleles driving proliferation; historically associated with poor prognosis and resistant to many targeted approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More frequent in older men, smokers, large/solid poorly differentiated ADCs; associated with poorer prognosis.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Attempts to target KRAS have been largely unsuccessful historically; no standard direct targeted therapy (as of paper).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS/exon sequencing; targeted PCR panels</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e25.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF V600E</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF V600E point mutation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Substitution of valine->glutamate at codon 600 of BRAF, an activating mutation in the RAF kinase that occurs in a subset of lung adenocarcinomas and can be targeted by BRAF/MEK inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BRAF V600E (Val600Glu)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF / RAS → RAF → MEK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>7–10% (majority V600E in exon 15)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; clinical response to BRAF/MEK targeted therapy (trials reported)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Activating BRAF mutation; responsive to BRAF pathway inhibition (evidence from clinical cohorts and trials).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More likely observed in smokers and women (per paper); not associated with a clear prognostic change relative to wild-type.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable by BRAF inhibitors and combined BRAF+MEK therapy (dabrafenib + trametinib reported to have activity).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS/exon sequencing; clinical mutation tests</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e25.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NF1 mutation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neurofibromin 1 (NF1) loss/mutation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Loss-of-function mutations in NF1 (a negative regulator of RAS) found in lung adenocarcinoma that can deregulate RAS signaling and appear as a driver in a subset of tumors, sometimes in tumors lacking other canonical drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NF1 mutations / loss-of-function</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function mutation (tumor suppressor)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NF1 → negative regulator of RAS (RAS pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>TCGA 8.3%; cBioPortal ~11%</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>Paper notes ~70% of NF1-mutant lung cancers exhibit no other somatic alteration (i.e., frequently occur in tumors lacking other canonical drivers)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (TCGA); mutual exclusivity / co-occurrence analysis; clinical characterization</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>NF1 encodes neurofibromin, a negative regulator of RAS; loss expected to activate RAS signaling (functional regulatory role described in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>NF1-mutant patients have similar clinical characteristics and prognosis to KRAS-mutant patients; ~15% co-occurrence with KRAS when present.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Suggested as a potential therapeutic target based on genomic data (emerging); no specific approved targeted therapy described in paper.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA genomic sequencing; NGS panels</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e25.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MET exon 14 alterations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET exon 14 skipping mutations (MET ex14) / MET amplifications</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Alterations affecting MET exon 14 (splice-site/exon-skipping) and/or MET copy-number amplification that activate MET signaling; associated with poor prognosis and can mediate EGFR-TKI resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MET exon 14 alterations (splice/skipping) and MET amplification</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>splice-site/exon-skipping mutation (MET ex14) and copy number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MET receptor tyrosine kinase / RTK → downstream signaling (incl. RAS/MAPK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>MET ex14: TCGA 4.3%; cBioPortal ~8%; MET amplification: TCGA 2.2%; cBioPortal ~4%</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; clinical correlations; early therapeutic reports</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>MET amplifications associated with resistance to EGFR TKIs; MET exon 14 alterations are considered activating (paper notes promising evidence of crizotinib activity in MET exon 14-altered tumors).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>High MET copy number associated with worse prognosis; MET amplifications can mediate resistance to EGFR-targeted therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Emerging targetability: crizotinib reported promising evidence for MET exon 14 alterations and amplification.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS/exome sequencing (TCGA), copy-number analysis, FISH for amplification in clinical practice</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e25.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ALK fusion (EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Anaplastic lymphoma kinase (ALK) gene fusions, most commonly EML4-ALK</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Gene rearrangements that create constitutively active ALK fusion kinases (e.g., EML4-ALK) that drive oncogenic signaling in a subset of lung adenocarcinomas and predict robust responses to ALK inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ALK gene fusions (EML4-ALK and ~30 different fusion partners)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / translocation (oncogenic fusion)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK receptor tyrosine kinase / RTK → downstream pathways including RAS/RAF/MEK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>TCGA ~1.3%; cBioPortal ~3-8%</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; clinical response to ALK inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Fusion proteins produce constitutive ALK kinase activity driving tumor growth; clinical responses to ALK inhibitors demonstrate oncogenic role.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Found in younger patients, never-smokers, more often women; tumors often moderately/poorly differentiated and peripheral; generally mutually exclusive with KRAS/EGFR.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable by ALK inhibitors (crizotinib, ceritinib, alectinib).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FISH, IHC, PCR, NGS for fusion detection (paper mentions FISH/PCR/IHC as tools)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e25.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS1 fusion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 gene rearrangements / fusions (e.g., CD74-ROS1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ROS1 gene fusions with various partners produce oncogenic ROS1 kinases in a small subset of lung adenocarcinomas and predict sensitivity to ROS1 inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ROS1 gene fusions (e.g., CD74-ROS1, EZR-ROS1, SLC24A2-ROS1, FIG-ROS1)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / translocation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 receptor tyrosine kinase / RTK → downstream signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>TCGA ~1.7%; cBioPortal ~2%</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; clinical response to ROS1 inhibitor (crizotinib)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Fusion kinases activate ROS1 signaling; clinical responses to crizotinib support driver role.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Associated with ADC histology, often in younger, never-smoker, Asian women according to paper.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Targetable by crizotinib (approved for ROS1-rearranged NSCLC).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FISH, PCR, NGS; clinical testing modalities noted in paper</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e25.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RET fusion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RET gene rearrangements / fusions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Rearrangements involving the RET tyrosine kinase gene that occur at low frequency in lung adenocarcinoma and represent targetable oncogenic fusions in some cases.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RET gene fusions (rearrangements encoding constitutively active RET kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / translocation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RET receptor tyrosine kinase / RTK → downstream signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>TCGA ~0.9%; cBioPortal ~1%</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; recognized as oncogenic fusion in ADC</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Described among targetable kinase fusions (therapeutic approaches not detailed in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Genomic profiling; FISH/NGS for rearrangement detection</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e25.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ERBB2 (HER2)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 / HER2 mutations and amplifications</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Alterations of ERBB2 (HER2) in lung adenocarcinoma include activating mutations and rare amplifications; ERBB2 is a member of the EGFR family and may be targetable.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 (HER2) activating mutations and amplifications</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (activating) and copy number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 (HER2) / EGFR family RTK → downstream pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Mutations: TCGA 1.7% (cBioPortal ~1%); Amplifications: TCGA 0.9% (cBioPortal ~3%)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling; listed among targetable receptor tyrosine kinases</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ERBB2 alterations considered potentially targetable (no specific approved agent cited in paper for lung ADC).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS/exome sequencing; copy-number analysis; clinical assays</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e25.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RIT1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RIT1 mutations (Ras-like GTPase RIT1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mutations in RIT1, a RAS-family GTPase, are reported at low frequency in lung adenocarcinoma and represent an alternative RAS-pathway activating event.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RIT1 mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating, presumed)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RIT1 / RAS-like small GTPase → downstream RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>TCGA ~2.2%; cBioPortal ~2%</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (TCGA/cBioPortal listing)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Emerging/rare RAS-pathway driver; therapeutic implications not detailed in paper.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA NGS/exome data; cBioPortal aggregation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e25.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MAP2K1 (MEK1)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MAP2K1 (MEK1) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Rare mutations in MAP2K1 (encoding MEK1) occur in a small fraction of lung adenocarcinomas and represent alterations in the RAF→MEK→ERK signaling axis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MAP2K1 mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating / pathway alteration)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MAP2K1 (MEK1) / RAF→MEK→ERK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>TCGA 0.9%; cBioPortal <1%</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (TCGA/cBioPortal)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Perturbs MAPK pathway; potential to be targeted by MEK pathway inhibitors (not detailed in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS/exome (TCGA); targeted panels</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e25.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NRAS/HRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NRAS and HRAS mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Rare activating mutations in NRAS or HRAS are occasionally observed in lung adenocarcinoma and represent alternative RAS-pathway drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NRAS and HRAS point mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NRAS/HRAS / RAS → RAF → MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>TCGA 0.8%; cBioPortal <1%</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (TCGA/cBioPortal)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Represent rare RAS-pathway activations; no specific therapeutic guidance in paper.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>NGS/exome sequencing; targeted panels</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.14">
                <h3 class="extraction-instance">Extracted Data Instance 14 (e25.14)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TP53</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tumor suppressor p53 (TP53) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Loss-of-function mutations in TP53 are common in lung adenocarcinoma and represent frequent co-occurring alterations that contribute to genomic instability and tumor progression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TP53 mutations (loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations / loss-of-function in a tumor suppressor</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TP53 (tumor suppressor) — genome stability / cell cycle / apoptosis pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>TCGA reports TP53 mutated in ~35% of lung ADC (paper states 35%)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (TCGA)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>TP53 mutation contributes to genomic instability and increases cancer susceptibility; classical tumor suppressor role described.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Common across ADC; overlaps with oncogenic driver alterations such as KRAS, EGFR, BRAF, MET, ERBB2, ALK, ROS1, RET.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>TCGA whole-exome sequencing; NGS</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e25.15">
                <h3 class="extraction-instance">Extracted Data Instance 15 (e25.15)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TERT / CLPTM1L SNPs</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>TERT and CLPTM1L germline polymorphisms (GWAS loci)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Germline SNPs at 5p15.33 (TERT) and nearby CLPTM1L have been associated with increased lung cancer susceptibility, particularly adenocarcinoma in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Germline SNPs in TERT and CLPTM1L (GWAS-identified risk variants)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>germline polymorphism / susceptibility locus</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TERT (telomerase) / CLPTM1L (unknown function related to cancer susceptibility)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genome-wide association studies (GWAS)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Associated with increased risk and higher DNA adduct formation (cited evidence); TERT polymorphisms linked especially to ADC in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Germline risk factor, especially for adenocarcinoma in never-smokers and across ethnicities.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>GWAS / population genetic studies</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.', 'publication_date_yy_mm': '2017-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Comprehensive molecular profiling of lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Genomic alterations in lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer <em>(Rating: 2)</em></li>
                <li>Targeting MET in Lung Cancer: Will Expectations Finally Be MET? <em>(Rating: 2)</em></li>
                <li>Crizotinib in ROS1 -Rearranged Non-Small-Cell Lung Cancer <em>(Rating: 2)</em></li>
                <li>Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial <em>(Rating: 2)</em></li>
                <li>Comprehensive identification of mutational cancer driver genes across 12 tumor types <em>(Rating: 2)</em></li>
                <li>Epidermal growth factor receptor mutations in lung cancer <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>